Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 27, 2020March 27, 2020

Voclosporin Helps Protect Kidneys in Lupus Nephritis, Phase 3 Trial Shows

News

Adding the experimental oral therapy voclosporin to standard treatment is safe, and its use more than doubles complete kidney responses in people with lupus nephritis, results from the Phase 3 AURORA ... Read more

February 24, 2020February 24, 2020

Better Counseling of Lupus Patients Likely When Greater Range Given to CLE Scales, Study Says

News

More stringent thresholds in the Cutaneous Lupus Activity and Severity Index (CLASI), a common tool to assess disease progression and treatment response in cutaneous lupus erythematosus (CLE), can better identify ... Read more

February 19, 2020February 19, 2020

Treatment Toxicity, Age Linked to Eye Complications in SLE, Study Finds

News

While people with systemic lupus erythematous lupus (SLE) are experiencing fewer eye complications directly linked to the disease, treatment-induced eye toxicity and age-related eye complications are becoming more frequent, a ... Read more

February 7, 2020February 7, 2020

Blood Levels of Galectin-9 May Help Spot SLE Patients with More Severe Disease, Study Suggests

News

Elevated blood levels of a marker called galectin-9 may help identify people with systemic lupus erythematous lupus (SLE) who have more active disease and organ damage, a study suggests. The ... Read more

January 24, 2020January 24, 2020

Early Onset of Renal Arteriosclerosis, Hardening of Kidney Arteries, Found in Lupus Nephritis, Study Shows

News

Hardening of the kidney arteries, a condition called renal arteriosclerosis, is detected two decades earlier in people with lupus nephritis compared with healthy individuals, a study shows. The study, “High ... Read more

November 11, 2019November 11, 2019

Blood Protein Levels Linked to Disease Activity in Children with SLE and May Be Biomarkers, Study Reports

News

Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium — are higher in children and adolescents with systemic lupus erythematosus (SLE) and are ... Read more

November 4, 2019November 4, 2019

Using Hydroxychloroquine for Less Than 1 Year Raises Patients’ Likelihood of Flares, Study Suggests

News

People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start are at a higher risk of flares than those who continue using ... Read more

October 30, 2019December 5, 2019

More Than 40% of SLE Patients Do Not Adhere to Hydroxychloroquine Therapy, Study Reports

News

More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among people who have insurance coverage, low copayments, and availability of high levels ... Read more

October 28, 2019October 28, 2019

Phase 3 Trial of Voclosporin for Lupus Nephritis Completes Study Visits, Results Expected Soon

News

A Phase 3 trial assessing the potential of voclosporin as an add-on to standard treatment for people with lupus nephritis has completed patient visits. “With the completion of patient visits ... Read more

October 21, 2019

Apellis Stopping Development of APL-2 for Lupus Nephritis After Completion of Phase 2 Trial

News

Apellis Pharmaceuticals has decided to stop the development of an experimental therapy known as APL-2 for lupus nephritis and primary membranous nephropathy after the completion of an ongoing Phase 2 ... Read more